Psoriasis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Description

List of Tables

The report provides revenue of the global psoriasis treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global psoriasis treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the psoriasis treatment market.

The report delves into the competitive landscape of the global psoriasis treatment market. Key players operating in the global psoriasis treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global psoriasis treatment market profiled in this report.

Product Code: TMRGL17960

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Psoriasis Treatment Market

4. Market Overview

4.1. Introduction
- 4.1.1. Drug Class Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Psoriasis Treatment Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Mn)
- 4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter's Five Force Analysis

5. Key Insights

5.1. Regulatory Scenario by Region/Key Country
5.2. Pipeline Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Impact Analysis

6. Global Psoriasis Treatment Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
- 6.3.1. TNF Inhibitors
- 6.3.2. Interleukin Inhibitors
- 6.3.3. Vitamin D Analogs
- 6.3.4. Corticosteroids
- 6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class

7. Global Psoriasis Treatment Market Analysis and Forecast, by Route of Administration

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017-2031
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.3.3. Topical
7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Psoriasis Treatment Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Others
8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Psoriasis Treatment Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Psoriasis Treatment Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017-2031
- 10.2.1. TNF Inhibitors
- 10.2.2. Interleukin Inhibitors
- 10.2.3. Vitamin D Analogs
- 10.2.4. Corticosteroids
- 10.2.5. Others
10.3. Market Value Forecast, by Route of Administration, 2017-2031
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.3.3. Topical
10.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Others
10.5. Market Value Forecast, by Country, 2017-2031
- 10.5.1. U.S.
- 10.5.2. Canada
10.6. Market Attractiveness Analysis
- 10.6.1. By Drug Class
- 10.6.2. By Route of Administration
- 10.6.3. By Distribution Channel
- 10.6.4. By Country

11. Europe Psoriasis Treatment Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
- 11.2.1. TNF Inhibitors
- 11.2.2. Interleukin Inhibitors
- 11.2.3. Vitamin D Analogs
- 11.2.4. Corticosteroids
- 11.2.5. Others
11.3. Market Value Forecast, by Route of Administration, 2017-2031
- 11.3.1. Oral
- 11.3.2. Parenteral
- 11.3.3. Topical
11.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.4.1. Hospital Pharmacies
- 11.4.2. Retail Pharmacies
- 11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Spain
- 11.5.5. Italy
- 11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
- 11.6.1. By Drug Class
- 11.6.2. By Route of Administration
- 11.6.3. By Distribution Channel
- 11.6.4. By Country/Sub-region

12. Asia Pacific Psoriasis Treatment Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
- 12.2.1. TNF Inhibitors
- 12.2.2. Interleukin Inhibitors
- 12.2.3. Vitamin D Analogs
- 12.2.4. Corticosteroids
- 12.2.5. Others
12.3. Market Value Forecast, by Route of Administration, 2017-2031
- 12.3.1. Oral
- 12.3.2. Parenteral
- 12.3.3. Topical
12.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.4.1. Hospital Pharmacies
- 12.4.2. Retail Pharmacies
- 12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
- 12.6.1. By Drug Class
- 12.6.2. By Route of Administration
- 12.6.3. By Distribution Channel
- 12.6.4. By Country/Sub-region

13. Latin America Psoriasis Treatment Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
- 13.2.1. TNF Inhibitors
- 13.2.2. Interleukin Inhibitors
- 13.2.3. Vitamin D Analogs
- 13.2.4. Corticosteroids
- 13.2.5. Others
13.3. Market Value Forecast, by Route of Administration, 2017-2031
- 13.3.1. Oral
- 13.3.2. Parenteral
- 13.3.3. Topical
13.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.4.1. Hospital Pharmacies
- 13.4.2. Retail Pharmacies
- 13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
- 13.6.1. By Drug Class
- 13.6.2. By Route of Administration
- 13.6.3. By Distribution Channel
- 13.6.4. By Country/Sub-region

14. Middle East & Africa Psoriasis Treatment Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
- 14.2.1. TNF Inhibitors
- 14.2.2. Interleukin Inhibitors
- 14.2.3. Vitamin D Analogs
- 14.2.4. Corticosteroids
- 14.2.5. Others
14.3. Market Value Forecast, by Route of Administration, 2017-2031
- 14.3.1. Oral
- 14.3.2. Parenteral
- 14.3.3. Topical
14.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.4.1. Hospital Pharmacies
- 14.4.2. Retail Pharmacies
- 14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
- 14.6.1. By Drug Class
- 14.6.2. By Route of Administration
- 14.6.3. By Distribution Channel
- 14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
- 15.3.1. Amgen, Inc.
  - 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.1.2. Product Portfolio
  - 15.3.1.3. SWOT Analysis
  - 15.3.1.4. Strategic Overview
- 15.3.2. AstraZeneca plc
  - 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.2.2. Product Portfolio
  - 15.3.2.3. SWOT Analysis
  - 15.3.2.4. Strategic Overview
- 15.3.3. AbbVie, Inc.
  - 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.3.2. Product Portfolio
  - 15.3.3.3. SWOT Analysis
  - 15.3.3.4. Strategic Overview
- 15.3.4. Eli Lilly and Company
  - 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.4.2. Product Portfolio
  - 15.3.4.3. SWOT Analysis
  - 15.3.4.4. Strategic Overview
- 15.3.5. Johnson & Johnson
  - 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.5.2. Product Portfolio
  - 15.3.5.3. SWOT Analysis
  - 15.3.5.4. Strategic Overview
- 15.3.6. Biogen, Inc.
  - 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.6.2. Product Portfolio
  - 15.3.6.3. SWOT Analysis
  - 15.3.6.4. Strategic Overview
- 15.3.7. Novartis AG
  - 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.7.2. Product Portfolio
  - 15.3.7.3. SWOT Analysis
  - 15.3.7.4. Strategic Overview
- 15.3.8. Merck & Co., Inc.
  - 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.8.2. Product Portfolio
  - 15.3.8.3. SWOT Analysis
  - 15.3.8.4. Strategic Overview
- 15.3.9. Pfizer, Inc.
  - 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.9.2. Product Portfolio
  - 15.3.9.3. SWOT Analysis
  - 15.3.9.4. Strategic Overview
- 15.3.10. LEO Pharma A/S
  - 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 15.3.10.2. Product Portfolio
  - 15.3.10.3. SWOT Analysis
  - 15.3.10.4. Strategic Overview
- 15.3.11. Other Players